Cargando…

DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia

BACKGROUND: Abnormal alternative splicing is frequently associated with carcinogenesis. In B‐cell acute lymphoblastic leukemia (B‐ALL), double homeobox 4 fused with immunoglobulin heavy chain (DUX4/IGH) can lead to the aberrant production of E‐26 transformation‐specific family related gene abnormal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Cheng, Nuo, Li, Zhihui, Bai, Ling, Fang, Chengli, Li, Yuwen, Zhang, Weina, Dong, Xue, Jiang, Minghao, Liang, Yang, Zhang, Sujiang, Mi, Jianqing, Zhu, Jiang, Zhang, Yu, Chen, Sai‐Juan, Zhao, Yajie, Weng, Xiang‐Qin, Hu, Weiguo, Chen, Zhu, Huang, Jinyan, Meng, Guoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626599/
https://www.ncbi.nlm.nih.gov/pubmed/34699692
http://dx.doi.org/10.1002/cac2.12234
_version_ 1784606688403259392
author Zhang, Hao
Cheng, Nuo
Li, Zhihui
Bai, Ling
Fang, Chengli
Li, Yuwen
Zhang, Weina
Dong, Xue
Jiang, Minghao
Liang, Yang
Zhang, Sujiang
Mi, Jianqing
Zhu, Jiang
Zhang, Yu
Chen, Sai‐Juan
Zhao, Yajie
Weng, Xiang‐Qin
Hu, Weiguo
Chen, Zhu
Huang, Jinyan
Meng, Guoyu
author_facet Zhang, Hao
Cheng, Nuo
Li, Zhihui
Bai, Ling
Fang, Chengli
Li, Yuwen
Zhang, Weina
Dong, Xue
Jiang, Minghao
Liang, Yang
Zhang, Sujiang
Mi, Jianqing
Zhu, Jiang
Zhang, Yu
Chen, Sai‐Juan
Zhao, Yajie
Weng, Xiang‐Qin
Hu, Weiguo
Chen, Zhu
Huang, Jinyan
Meng, Guoyu
author_sort Zhang, Hao
collection PubMed
description BACKGROUND: Abnormal alternative splicing is frequently associated with carcinogenesis. In B‐cell acute lymphoblastic leukemia (B‐ALL), double homeobox 4 fused with immunoglobulin heavy chain (DUX4/IGH) can lead to the aberrant production of E‐26 transformation‐specific family related gene abnormal transcript (ERG(alt)) and other splicing variants. However, the molecular mechanism underpinning this process remains elusive. Here, we aimed to know how DUX4/IGH triggers abnormal splicing in leukemia. METHODS: The differential intron retention analysis was conducted to identify novel DUX4/IGH‐driven splicing in B‐ALL patients. X‐ray crystallography, small angle X‐ray scattering (SAXS), and analytical ultracentrifugation were used to investigate how DUX4/IGH recognize double DUX4 responsive element (DRE)‐DRE sites. The ERG(alt) biogenesis and B‐cell differentiation assays were performed to characterize the DUX4/IGH crosslinking activity. To check whether recombination‐activating gene 1/2 (RAG1/2) was required for DUX4/IGH‐driven splicing, the proximity ligation assay, co‐immunoprecipitation, mammalian two hybrid characterizations, in vitro RAG1/2 cleavage, and shRNA knock‐down assays were performed. RESULTS: We reported previously unrecognized intron retention events in C‐type lectin domain family 12, member A abnormal transcript (CLEC12A(alt)) and chromosome 6 open reading frame 89 abnormal transcript (C6orf89(alt)), where also harbored repetitive DRE‐DRE sites. Supportively, X‐ray crystallography and SAXS characterization revealed that DUX4 homeobox domain (HD)1‐HD2 might dimerize into a dumbbell‐shape trans configuration to crosslink two adjacent DRE sites. Impaired DUX4/IGH‐mediated crosslinking abolishes ERG(alt), CLEC12A(alt), and C6orf89(alt) biogenesis, resulting in marked alleviation of its inhibitory effect on B‐cell differentiation. Furthermore, we also observed a rare RAG1/2‐mediated recombination signal sequence‐like DNA edition in DUX4/IGH target genes. Supportively, shRNA knock‐down of RAG1/2 in leukemic Reh cells consistently impaired the biogenesis of ERG(alt), CLEC12A(alt), and C6orf89(alt). CONCLUSIONS: All these results suggest that DUX4/IGH‐driven DNA crosslinking is required for RAG1/2 recruitment onto the double tandem DRE‐DRE sites, catalyzing V(D)J‐like recombination and oncogenic splicing in acute lymphoblastic leukemia.
format Online
Article
Text
id pubmed-8626599
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86265992021-12-03 DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia Zhang, Hao Cheng, Nuo Li, Zhihui Bai, Ling Fang, Chengli Li, Yuwen Zhang, Weina Dong, Xue Jiang, Minghao Liang, Yang Zhang, Sujiang Mi, Jianqing Zhu, Jiang Zhang, Yu Chen, Sai‐Juan Zhao, Yajie Weng, Xiang‐Qin Hu, Weiguo Chen, Zhu Huang, Jinyan Meng, Guoyu Cancer Commun (Lond) Original Articles BACKGROUND: Abnormal alternative splicing is frequently associated with carcinogenesis. In B‐cell acute lymphoblastic leukemia (B‐ALL), double homeobox 4 fused with immunoglobulin heavy chain (DUX4/IGH) can lead to the aberrant production of E‐26 transformation‐specific family related gene abnormal transcript (ERG(alt)) and other splicing variants. However, the molecular mechanism underpinning this process remains elusive. Here, we aimed to know how DUX4/IGH triggers abnormal splicing in leukemia. METHODS: The differential intron retention analysis was conducted to identify novel DUX4/IGH‐driven splicing in B‐ALL patients. X‐ray crystallography, small angle X‐ray scattering (SAXS), and analytical ultracentrifugation were used to investigate how DUX4/IGH recognize double DUX4 responsive element (DRE)‐DRE sites. The ERG(alt) biogenesis and B‐cell differentiation assays were performed to characterize the DUX4/IGH crosslinking activity. To check whether recombination‐activating gene 1/2 (RAG1/2) was required for DUX4/IGH‐driven splicing, the proximity ligation assay, co‐immunoprecipitation, mammalian two hybrid characterizations, in vitro RAG1/2 cleavage, and shRNA knock‐down assays were performed. RESULTS: We reported previously unrecognized intron retention events in C‐type lectin domain family 12, member A abnormal transcript (CLEC12A(alt)) and chromosome 6 open reading frame 89 abnormal transcript (C6orf89(alt)), where also harbored repetitive DRE‐DRE sites. Supportively, X‐ray crystallography and SAXS characterization revealed that DUX4 homeobox domain (HD)1‐HD2 might dimerize into a dumbbell‐shape trans configuration to crosslink two adjacent DRE sites. Impaired DUX4/IGH‐mediated crosslinking abolishes ERG(alt), CLEC12A(alt), and C6orf89(alt) biogenesis, resulting in marked alleviation of its inhibitory effect on B‐cell differentiation. Furthermore, we also observed a rare RAG1/2‐mediated recombination signal sequence‐like DNA edition in DUX4/IGH target genes. Supportively, shRNA knock‐down of RAG1/2 in leukemic Reh cells consistently impaired the biogenesis of ERG(alt), CLEC12A(alt), and C6orf89(alt). CONCLUSIONS: All these results suggest that DUX4/IGH‐driven DNA crosslinking is required for RAG1/2 recruitment onto the double tandem DRE‐DRE sites, catalyzing V(D)J‐like recombination and oncogenic splicing in acute lymphoblastic leukemia. John Wiley and Sons Inc. 2021-10-26 /pmc/articles/PMC8626599/ /pubmed/34699692 http://dx.doi.org/10.1002/cac2.12234 Text en © 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zhang, Hao
Cheng, Nuo
Li, Zhihui
Bai, Ling
Fang, Chengli
Li, Yuwen
Zhang, Weina
Dong, Xue
Jiang, Minghao
Liang, Yang
Zhang, Sujiang
Mi, Jianqing
Zhu, Jiang
Zhang, Yu
Chen, Sai‐Juan
Zhao, Yajie
Weng, Xiang‐Qin
Hu, Weiguo
Chen, Zhu
Huang, Jinyan
Meng, Guoyu
DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
title DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
title_full DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
title_fullStr DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
title_full_unstemmed DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
title_short DNA crosslinking and recombination‐activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
title_sort dna crosslinking and recombination‐activating genes 1/2 (rag1/2) are required for oncogenic splicing in acute lymphoblastic leukemia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626599/
https://www.ncbi.nlm.nih.gov/pubmed/34699692
http://dx.doi.org/10.1002/cac2.12234
work_keys_str_mv AT zhanghao dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT chengnuo dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT lizhihui dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT bailing dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT fangchengli dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT liyuwen dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT zhangweina dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT dongxue dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT jiangminghao dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT liangyang dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT zhangsujiang dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT mijianqing dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT zhujiang dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT zhangyu dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT chensaijuan dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT zhaoyajie dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT wengxiangqin dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT huweiguo dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT chenzhu dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT huangjinyan dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia
AT mengguoyu dnacrosslinkingandrecombinationactivatinggenes12rag12arerequiredforoncogenicsplicinginacutelymphoblasticleukemia